Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
Created page with "=====Malaria Vaccine===== [https://en.wikipedia.org/wiki/Malaria_vaccine by Wikipedia] A Malaria vaccine is a vaccine that prevents malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria-endemic countries and areas and caused 608,000 deaths in 2022. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in a..." |
No edit summary |
||
| Line 2: | Line 2: | ||
[https://en.wikipedia.org/wiki/Malaria_vaccine by Wikipedia] | [https://en.wikipedia.org/wiki/Malaria_vaccine by Wikipedia] | ||
A Malaria vaccine is a vaccine that prevents malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria-endemic countries and areas and caused 608,000 deaths in 2022. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% | A Malaria vaccine is a vaccine that prevents malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria-endemic countries and areas and caused 608,000 deaths in 2022. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% | ||
=====GLOBAL TECHNICAL STRATEGY FOR MALARIA===== | |||
[https://www.iom.int/sites/g/files/tmzbdl2616/files/2018-07/9789241564991_eng.pdf by World Health Organization] | |||
The designations employed and the presentation of the material in this publication do not imply the expression | |||
of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any | |||
country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. | |||
Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full | |||
agreement. | |||
Revision as of 18:58, 14 November 2025
Malaria Vaccine
A Malaria vaccine is a vaccine that prevents malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria-endemic countries and areas and caused 608,000 deaths in 2022. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%
GLOBAL TECHNICAL STRATEGY FOR MALARIA
The designations employed and the presentation of the material in this publication do not imply the expression
of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
